Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Heartbeam Inc (NQ: BEAT )

2.214 -0.176 (-7.37%)
Streaming Delayed Price Updated: 12:24 PM EDT, Aug 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Heartbeam Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
HeartBeam Inc. (NASDAQ: BEAT) Granted Patent for Proprietary ECG Smartwatch-Based Monitor Designed for Heart Attack Detection
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Adds Renowned Cardiologist to Help Define Best Paths to Advance Products
Via Investor Brand Network
HeartBeam (NASDAQ: BEAT) Looks to Disrupt Multi-Billion-Dollar Patch Market with its Patent-Protected 12-Lead ECG Patch Product
Monitoring a patient’s heart condition is an extensive undertaking considering the current standard of care practices. Up until a few years ago, heart patients seeking to have their condition monitored... 
Via Benzinga
HeartBeam (NASDAQ: BEAT) Stands to Disrupt to Multi-Billion-Dollar Patch Market with its Patent-Protected 12-Lead ECG Patch Product
Monitoring a patient’s heart condition is an extensive undertaking considering the current standard of care practices. Up until a few 
Via Spotlight Growth
New Research Finds Gaming Can Cause Fatal Arrhythmias
Via Investor Brand Network
HeartBeam (NASDAQ: BEAT): Innovative Technologies Disrupting the Old Standard of Care for Heart Patients and Upgrading ECG for the 21st Century
The heart is one of the most essential organs that propel life by pumping blood throughout the body and supporting 
Via Spotlight Growth
Topics Death
Exposures Death
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Signs Agreement to Build Exclusive AIMIGo 12-Lead 3D VECG Device
Via Investor Brand Network
Topics Supply Chain
Exposures Product Safety Supply Chain
HeartBeam (NASDAQ: BEAT) Partners with Evolve Manufacturing to Build HeartBeam AIMIGoTM 12-Lead 3D Vector Electrocardiogram Device
SANTA CLARA, Calif., December 07, 2022--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and 
Via Spotlight Growth
Topics Supply Chain
Exposures Product Safety Supply Chain
HeartBeam Partners with Evolve Manufacturing to Build HeartBeam AIMIGoTM 12-Lead 3D Vector Electrocardiogram Device
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Recognized for ‘Unique Approach to Heart Attack Diagnosis’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam Inc. (NASDAQ: BEAT) Announces New Chief Medical Officer
Via Investor Brand Network
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
Via Benzinga
HeartBeam Inc. (NASDAQ: BEAT) Awarded Top Honors for Game-Changing Cardiovascular Tech Platform
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. 
Via Benzinga
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Expands Growing Portfolio with Valuable New Patent
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam Snags New Patent For 12-Lead ECG Smartwatch-Based Monitor To Detect Heart Attacks
HeartBeam Inc (NASDAQ: BEAT) announced that its patent for a 12-lead electrocardiogram (ECG) smartwatch-based monitor intended to detect heart attacks and complex cardiac arrhythmias was allowed by the... 
Via Benzinga
New HeartBeam Patent for 12-Lead Electrocardiogram (ECG) Smartwatch-based Monitor Intended for Detection of Heart Attacks and Complex Cardiac Arrhythmias
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q3 2022 Financial Report
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
HeartBeam Reports Third Quarter 2022 Financial Results
From HeartBeam, Inc.
Via Business Wire
Study Finds Covid-19 Spikes Linked to Increases in Heart Attacks
Via Investor Brand Network
Exposures COVID-19
Study Finds Smart Watches Can Accurately Detect Atrial Fibrillation
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q3 2022 Results Conference Call
Via Investor Brand Network
HeartBeam to Host Third Quarter 2022 Results Conference Call on Thursday November 10, 2022 at 4:30 p.m. Eastern Time
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) Patented Breakthrough Technology Poised to Disrupt ECG Patch Market
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Featured in BioWorld(TM) MedTech Article
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Virgin Orbit And 4 More Short Squeeze Stocks That Could Soar This Week — Including A Stock Moving Up 968 Positions
Potential short squeeze plays gained steam in 2021 and has continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates based on the... 
Via Benzinga
GLSI, AVTE: The Top 5 Short Squeeze Stocks to Watch This Week
Short-squeeze stocks continue to be a big deal for speculative traders and we're helping them out with a list to keep in mind this week! 
Via InvestorPlace
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Participate at Upcoming LD Micro Main Event XV Conference
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.